PRLD PRLD
Company Profile ↓Company Overview
PRLD (PRLD) is a publicly traded company listed on with a market capitalization of $285.81M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.26.
Recent Developments
- Dec 2025 Revenue of $12.14M (+73.4% YoY); net profit $-99.50M.
- Trailing 12 Months Year-on-year growth — revenue +73.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 73.43% |
Stock Price Performance
| 1 Year: | +436.64% |
| 6 Months: | +98.25% |
| 3 Months: | -2.78% |
| 1 Month: | -8.65% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)52.29 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.00M | 0 | 0 | 6.50M | 5.64M | 4.58M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 34.61M | 32.19M | 26.92M | 22.99M | 18.76M |
| Operating Income | - | - | -6.88M | -9.74M | -11.44M | -18.14M | -21.97M | -27.92M | -30.84M | -30.29M | -29.46M | -30.41M | -29.11M | -32.40M | -33.38M | -34.34M | -37.16M | -34.38M | -34.61M | -32.19M | -20.42M | -17.35M | -14.18M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -34.17M | -31.76M | -19.99M | -16.93M | -13.79M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -32.09M | -31.23M | -19.73M | -16.46M | -10.38M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -5.24M | -5.56M | -6.73M | -9.51M | -11.41M | -16.76M | -21.30M | -26.86M | -30.69M | -29.46M | -27.37M | -29.96M | -27.72M | -30.43M | -30.61M | -31.43M | -34.74M | -32.27M | -32.09M | -31.23M | -19.73M | -16.46M | -10.38M |
| Diluted EPS | - | - | - | - | - | - | - | -0.58 | -0.66 | -0.63 | -0.58 | -0.63 | -0.58 | -0.54 | -0.45 | -0.42 | -0.46 | -0.43 | -0.42 | -0.41 | -0.26 | - | -0.13 |
| R&D Expense | - | - | 5.49M | 8.54M | 9.78M | 15.29M | 16.47M | 22.41M | 22.72M | 22.82M | 21.31M | 22.89M | 21.83M | 24.97M | 26.26M | 27.41M | 29.51M | 29.46M | 28.82M | 25.78M | 21.71M | - | 13.60M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 0 | 0 | 7.00M | 12.14M |
| Cost of Revenue | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | 123.54M | 132.28M | 146.71M | 116.71M |
| Operating Income | -28.11M | -58.76M | -113.73M | -123.54M | -132.28M | -139.71M | -104.57M |
| EBITDA | - | - | - | -122.22M | -131.11M | -137.94M | -102.86M |
| Interest Expense | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | -115.44M | -121.83M | -127.17M | -99.50M |
| Tax Provision | - | - | - | - | - | - | - |
| Net Income | -27.57M | -56.93M | -111.69M | -115.44M | -121.83M | -127.17M | -99.50M |
| Diluted EPS | - | - | -2.43 | -2.44 | -2.02 | -1.68 | -1.29 |
| R&D Expense | 24.28M | 48.18M | 86.78M | 92.89M | 103.39M | 118.00M | 94.30M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 21.87M | 223.59M | - | 220.50M | 277.67M | 175.51M | 141.31M |
| Current Assets | - | - | - | - | 204.38M | 235.59M | 135.90M | 105.69M |
| Cash & Equivalents | - | 18.88M | 218.31M | - | 30.61M | 25.29M | 12.47M | 35.26M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - |
| Total Liabilities | - | 4.84M | 11.41M | - | 25.06M | 40.58M | 44.06M | 72.68M |
| Current Liabilities | - | 4.83M | 11.38M | - | 21.70M | 21.83M | 25.64M | 52.99M |
| Long Term Debt | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | 1.83M | 16.89M | 18.02M | 17.79M |
| Total Equity | -22.69M | -49.41M | 212.18M | - | 195.44M | 237.09M | 131.46M | 68.64M |
| Shares Outstanding | - | - | - | - | 47.90M | 54.91M | 55.15M | 62.95M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -25.66M | -46.18M | - | -83.73M | -107.06M | -102.89M | -56.30M |
| Investing Cash Flow | -780.00K | -621.00K | - | 81.69M | -34.65M | 90.19M | 53.46M |
| Financing Cash Flow | 29.73M | 246.23M | - | 815.00K | 136.40M | -120.00K | 24.82M |
| Capital Expenditure | -780.00K | -621.00K | - | -3.02M | -3.51M | -764.00K | -67.00K |
| Free Cash Flow | -26.45M | -46.80M | - | -86.75M | -110.58M | -103.65M | -56.37M |
| Net Change in Cash | - | - | - | -1.22M | -5.31M | -12.82M | 21.97M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | -1,995.9% | -861.3% |
| Net Margin % | - | - | - | - | - | -1,816.8% | -819.6% |
| ROE % | 55.8% | -26.8% | - | -59.1% | -51.4% | -96.7% | -145.0% |
| ROCE % | -165.0% | -27.7% | - | -62.1% | -51.7% | -93.2% | -118.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PRLD
Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?
The consensus price target hints at a 58.4% upside potential for Prelude Therapeutics (PRLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that t…
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why
Prelude Therapeutics (PRLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Goldman Sachs Initiates Coverage of Prelude Therapeutics (PRLD)
Prelude Therapeutics Incorporated (NASDAQ:PRLD) is one of the 10 Most Volatile Penny Stocks to Buy Now. On May 15, 2026, Goldman Sachs analyst Corinne Johnson initiated coverage of Prelude Therapeutics Incorporated (NASDAQ:PRLD) with an Ear…
Earnings Beat: Prelude Therapeutics Incorporated (NASDAQ:PRLD) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Last week, you might have seen that Prelude Therapeutics Incorporated ( NASDAQ:PRLD ) released its quarterly result to...
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF) The Company expects to file the IND for PRT13722, first-in-class highly-selective oral KA…
Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 33.6% in Prelude Therapeutics (PRLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estima…
PRLD — Frequently Asked Questions
What is the current share price of PRLD?
As of 2026-08-05 17:25 PDT, PRLD trades at $4.54 on NASDAQ/NYSE. Its 52-week range is $0.83 to $5.52.
What is the market capitalisation of PRLD?
PRLD has a market capitalisation of $285.81M on NASDAQ/NYSE.
What is the P/E ratio of PRLD?
PRLD trades at a trailing price-to-earnings (P/E) ratio of -3.52. Its price-to-book (P/B) ratio is 4.16.
What is the return on equity (ROE) of PRLD?
PRLD has a return on equity (ROE) of -144.96%. Its return on capital employed (ROCE) is -118.39%.
Is PRLD a good stock to buy?
This page provides a data-driven analysis of PRLD, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.